GLP-1 receptor agonist for appetite control and metabolic improvement
Review Required
No source PDF found. This guide was created from the Matrix seed list and Academy GLP-1 references. Dosing is based on standard clinical protocols and requires review for Matrix-specific protocol details.
Semaglutide is a GLP-1 receptor agonist that reduces appetite, slows gastric emptying, and improves insulin sensitivity. It is one of the most widely studied compounds in the GLP-1 class for weight management and metabolic health.
Activates GLP-1 receptors to suppress appetite centrally, slow gastric emptying (prolonging satiety), and enhance glucose-dependent insulin secretion. Improves overall insulin sensitivity and metabolic markers.
| Parameter | Details |
|---|---|
| Starting Dose | 0.25 mg weekly |
| Titration | Increase 0.25 mg every 4 weeks |
| Target Dose | 1.0–2.4 mg weekly |
| Frequency | Once weekly |
| Route | Subcutaneous (SubQ) injection |
Review Required
Dosing above reflects standard clinical protocols. Matrix-specific dosing protocol requires prescriber review and confirmation.
Do Not Stack
Do not stack with other GLP-1 receptor agonists.
FDA Black-Box Warning
FDA black-box warning exists across the entire GLP-1 class regarding thyroid C-cell tumors observed in rodent studies. No confirmed human signal. Prescriber authorization required.
Clinical Note
Monitor body composition, blood glucose, lipid panel, B12 levels, and GI tolerance. Prescriber authorization required for dose changes.
This guide is for educational and clinical-support purposes only. All dosing must be supervised by a licensed prescriber. Matrix Advanced Solutions does not provide medical advice. Always consult your healthcare provider before starting any peptide protocol.